Jim Simons Precision Biosciences Inc Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.29 - $0.45 $289,750 - $449,612	999,138 Added 62.76%	2,591,212 $946,000
Q3 2023 Nov 14, 2023	SELL	$0.34 - $0.69 $42,360 - $85,966	-124,589 Reduced 7.26%	1,592,074 $543,000
Q2 2023 Aug 11, 2023	BUY	$0.52 - $0.91 $98,969 - $173,195	190,325 Added 12.47%	1,716,663 $903,000
Q1 2023 May 12, 2023	SELL	$0.7 - $1.41 $38,080 - $76,704	-54,400 Reduced 3.44%	1,526,338 $1.15 Million
Q4 2022 Feb 13, 2023	SELL	$0.97 - $45.0 $574,170 - $26.6 Million	-591,928 Reduced 27.24%	1,580,738 $1.88 Million
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $1.54 Million - $51.6 Million	1,265,877 Added 139.6%	2,172,666 $2.82 Million
Q2 2022 Aug 12, 2022	BUY	$1.15 - $3.34 $774,424 - $2.25 Million	673,413 Added 288.55%	906,789 $1.45 Million
Q1 2022 May 13, 2022	BUY	$2.96 - $7.76 $630,408 - $1.65 Million	212,976 Added 1044.0%	233,376 $719,000
Q4 2021 Feb 11, 2022	BUY	$7.4 - $11.66 $150,960 - $237,864	20,400 New	20,400 $151,000
Q3 2021 Nov 12, 2021	SELL	$9.18 - $14.15 $928,327 - $1.43 Million	-101,125 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$8.07 - $12.52 $204,275 - $316,918	-25,313 Reduced 20.02%	101,125 $1.27 Million
Q1 2021 May 13, 2021	BUY	$8.57 - $15.79 $765,301 - $1.41 Million	89,300 Added 240.45%	126,438 $1.31 Million
Q4 2020 Feb 10, 2021	BUY	$5.98 - $12.47 $222,085 - $463,110	37,138 New	37,138 $310,000
Q2 2020 Aug 13, 2020	SELL	$4.66 - $8.7 $417,778 - $779,972	-89,652 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$5.05 - $15.01 $452,742 - $1.35 Million	89,652 New	89,652 $541,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $791M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.